Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture

IGFs are pleiotrophic mitogens for porcine smooth muscle cells (pSMC) in culture. The effects of IGFs on cells are modulated by various insulin-like growth factor-binding proteins (IGFBP). IGFBP-5 is synthesized by pSMC and binds to the extracellular matrix. However, IGFBP-5 is also secreted into co...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of clinical investigation 1997-11, Vol.100 (10), p.2596-2605
Hauptverfasser: Imai, Y, Busby, Jr, W H, Smith, C E, Clarke, J B, Garmong, A J, Horwitz, G D, Rees, C, Clemmons, D R
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2605
container_issue 10
container_start_page 2596
container_title The Journal of clinical investigation
container_volume 100
creator Imai, Y
Busby, Jr, W H
Smith, C E
Clarke, J B
Garmong, A J
Horwitz, G D
Rees, C
Clemmons, D R
description IGFs are pleiotrophic mitogens for porcine smooth muscle cells (pSMC) in culture. The effects of IGFs on cells are modulated by various insulin-like growth factor-binding proteins (IGFBP). IGFBP-5 is synthesized by pSMC and binds to the extracellular matrix. However, IGFBP-5 is also secreted into conditioned medium of cultured cells and is cleaved into fragments by a concomitantly produced protease. These fragments have reduced affinity for the IGFs and cleavage makes it difficult to assess the role of intact IGFBP-5. To study the consequence of accumulation of intact IGFBP-5 in medium, we determined the cleavage site in IGFBP-5 and prepared a protease resistant mutant. Amino acid sequencing of purified IGFBP-5 fragments suggested Arg138-Arg139 as the primary cleavage site. Arg138-Arg139-->Asn138-Asn139 mutations were introduced to create protease-resistant IGFBP-5, which has the same affinity for IGF-I as the native protein. This mutant IGFBP-5 remained intact even after 24 h of incubation and it inhibited several IGF-I actions when added to pSMC culture medium. The mutant IGFBP-5 (500 ng/ml) decreased IGF-I stimulated cellular DNA synthesis by 84%, protein synthesis by 77%, and it inhibited IGF-I stimulated migration of pSMC by 77%. It also inhibited IGF-I stimulation of IRS-1 phosphorylation. In contrast, the same amount of native IGFBP-5 did not inhibit IGF-I actions. The significance of inhibitory effects of the protease resistant IGFBP-5 was further demonstrated in pSMC transfected with mutant or native IGFBP-5 cDNAs. The mutant IGFBP-5 accumulated in culture medium of transfected cells, while native IGFBP-5 was degraded into fragments, PSMC overexpressing the mutant IGFBP-5 also responded poorly to IGF-I compared with mock transfected cells. IGF-I (5 ng/ml) increased [35S]methionine incorporation into control cells by 36% above the basal level, but it did not significantly change (4%) in pSMC cultures that were producing the mutant IGFBP-5. In conclusion, the accumulation of protease-resistant IGFBP-5 in the medium was inhibitory to IGF-I actions on pSMC. This suggests that proteolysis can prevent IGFBP-5 from acting as an inhibitor of IGF-I-stimulated effects and that it serves as an important mechanism for regulating cellular responsiveness to IGF-I.
doi_str_mv 10.1172/JCI119803
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_508461</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>9366575</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-37a1669115ec126dacda86b2935ba2c16c8420c701f4dd6b84d2d506b583be643</originalsourceid><addsrcrecordid>eNqFkbtOwzAYhT2ASikMPACSV4aAHV-SDAyo4lJUCQaYI9txWoNjR7YD4pF4S1K1qmBiOsP_fecfDgBnGF1iXORXj_MFxlWJyAGYIpTjrCpIeQSOY3xDCFPK6ARMKsI5K9gUfD8Hn7SIOgs6mpiES7D1oYO-hcbFwRqXWfOu4Sr4z7SGrVDJh0wa1xi3gv3GNg4yaCIUblTWRpqR-MdfwDGNdxF6B3sflHEaxs77EemGqKyGSlsbxw6oBpuGoE_AYSts1Ke7nIHXu9uX-UO2fLpfzG-WmSK8ShkpBOa8wphphXPeCNWIksu8IkyKXGGuSpojVSDc0qbhsqRN3jDEJSuJ1JySGbje9vaD7HSjtEtB2LoPphPhq_bC1H8vzqzrlf-oGSopx6N_sfVV8DEG3e5VjOrNQvV-oZE9__1rT-7mIT8okZML</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Imai, Y ; Busby, Jr, W H ; Smith, C E ; Clarke, J B ; Garmong, A J ; Horwitz, G D ; Rees, C ; Clemmons, D R</creator><creatorcontrib>Imai, Y ; Busby, Jr, W H ; Smith, C E ; Clarke, J B ; Garmong, A J ; Horwitz, G D ; Rees, C ; Clemmons, D R</creatorcontrib><description>IGFs are pleiotrophic mitogens for porcine smooth muscle cells (pSMC) in culture. The effects of IGFs on cells are modulated by various insulin-like growth factor-binding proteins (IGFBP). IGFBP-5 is synthesized by pSMC and binds to the extracellular matrix. However, IGFBP-5 is also secreted into conditioned medium of cultured cells and is cleaved into fragments by a concomitantly produced protease. These fragments have reduced affinity for the IGFs and cleavage makes it difficult to assess the role of intact IGFBP-5. To study the consequence of accumulation of intact IGFBP-5 in medium, we determined the cleavage site in IGFBP-5 and prepared a protease resistant mutant. Amino acid sequencing of purified IGFBP-5 fragments suggested Arg138-Arg139 as the primary cleavage site. Arg138-Arg139--&gt;Asn138-Asn139 mutations were introduced to create protease-resistant IGFBP-5, which has the same affinity for IGF-I as the native protein. This mutant IGFBP-5 remained intact even after 24 h of incubation and it inhibited several IGF-I actions when added to pSMC culture medium. The mutant IGFBP-5 (500 ng/ml) decreased IGF-I stimulated cellular DNA synthesis by 84%, protein synthesis by 77%, and it inhibited IGF-I stimulated migration of pSMC by 77%. It also inhibited IGF-I stimulation of IRS-1 phosphorylation. In contrast, the same amount of native IGFBP-5 did not inhibit IGF-I actions. The significance of inhibitory effects of the protease resistant IGFBP-5 was further demonstrated in pSMC transfected with mutant or native IGFBP-5 cDNAs. The mutant IGFBP-5 accumulated in culture medium of transfected cells, while native IGFBP-5 was degraded into fragments, PSMC overexpressing the mutant IGFBP-5 also responded poorly to IGF-I compared with mock transfected cells. IGF-I (5 ng/ml) increased [35S]methionine incorporation into control cells by 36% above the basal level, but it did not significantly change (4%) in pSMC cultures that were producing the mutant IGFBP-5. In conclusion, the accumulation of protease-resistant IGFBP-5 in the medium was inhibitory to IGF-I actions on pSMC. This suggests that proteolysis can prevent IGFBP-5 from acting as an inhibitor of IGF-I-stimulated effects and that it serves as an important mechanism for regulating cellular responsiveness to IGF-I.</description><identifier>ISSN: 0021-9738</identifier><identifier>DOI: 10.1172/JCI119803</identifier><identifier>PMID: 9366575</identifier><language>eng</language><publisher>United States</publisher><subject>Amino Acid Sequence ; Animals ; Aorta ; Arginine ; Asparagine ; Cell Division - drug effects ; Cells, Cultured ; Culture Media, Conditioned ; Humans ; Insulin-Like Growth Factor Binding Protein 1 - antagonists &amp; inhibitors ; Insulin-Like Growth Factor Binding Protein 1 - pharmacology ; Insulin-Like Growth Factor Binding Protein 5 - biosynthesis ; Insulin-Like Growth Factor Binding Protein 5 - chemistry ; Insulin-Like Growth Factor Binding Protein 5 - pharmacology ; Insulin-Like Growth Factor I - pharmacology ; Metalloendopeptidases - metabolism ; Muscle, Smooth, Vascular - cytology ; Muscle, Smooth, Vascular - drug effects ; Muscle, Smooth, Vascular - physiology ; Mutagenesis, Site-Directed ; Peptide Fragments - chemistry ; Peptide Fragments - pharmacology ; Point Mutation ; Recombinant Proteins - chemistry ; Recombinant Proteins - pharmacology ; Swine ; Thymidine - metabolism</subject><ispartof>The Journal of clinical investigation, 1997-11, Vol.100 (10), p.2596-2605</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c369t-37a1669115ec126dacda86b2935ba2c16c8420c701f4dd6b84d2d506b583be643</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC508461/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC508461/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,728,781,785,886,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9366575$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Imai, Y</creatorcontrib><creatorcontrib>Busby, Jr, W H</creatorcontrib><creatorcontrib>Smith, C E</creatorcontrib><creatorcontrib>Clarke, J B</creatorcontrib><creatorcontrib>Garmong, A J</creatorcontrib><creatorcontrib>Horwitz, G D</creatorcontrib><creatorcontrib>Rees, C</creatorcontrib><creatorcontrib>Clemmons, D R</creatorcontrib><title>Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture</title><title>The Journal of clinical investigation</title><addtitle>J Clin Invest</addtitle><description>IGFs are pleiotrophic mitogens for porcine smooth muscle cells (pSMC) in culture. The effects of IGFs on cells are modulated by various insulin-like growth factor-binding proteins (IGFBP). IGFBP-5 is synthesized by pSMC and binds to the extracellular matrix. However, IGFBP-5 is also secreted into conditioned medium of cultured cells and is cleaved into fragments by a concomitantly produced protease. These fragments have reduced affinity for the IGFs and cleavage makes it difficult to assess the role of intact IGFBP-5. To study the consequence of accumulation of intact IGFBP-5 in medium, we determined the cleavage site in IGFBP-5 and prepared a protease resistant mutant. Amino acid sequencing of purified IGFBP-5 fragments suggested Arg138-Arg139 as the primary cleavage site. Arg138-Arg139--&gt;Asn138-Asn139 mutations were introduced to create protease-resistant IGFBP-5, which has the same affinity for IGF-I as the native protein. This mutant IGFBP-5 remained intact even after 24 h of incubation and it inhibited several IGF-I actions when added to pSMC culture medium. The mutant IGFBP-5 (500 ng/ml) decreased IGF-I stimulated cellular DNA synthesis by 84%, protein synthesis by 77%, and it inhibited IGF-I stimulated migration of pSMC by 77%. It also inhibited IGF-I stimulation of IRS-1 phosphorylation. In contrast, the same amount of native IGFBP-5 did not inhibit IGF-I actions. The significance of inhibitory effects of the protease resistant IGFBP-5 was further demonstrated in pSMC transfected with mutant or native IGFBP-5 cDNAs. The mutant IGFBP-5 accumulated in culture medium of transfected cells, while native IGFBP-5 was degraded into fragments, PSMC overexpressing the mutant IGFBP-5 also responded poorly to IGF-I compared with mock transfected cells. IGF-I (5 ng/ml) increased [35S]methionine incorporation into control cells by 36% above the basal level, but it did not significantly change (4%) in pSMC cultures that were producing the mutant IGFBP-5. In conclusion, the accumulation of protease-resistant IGFBP-5 in the medium was inhibitory to IGF-I actions on pSMC. This suggests that proteolysis can prevent IGFBP-5 from acting as an inhibitor of IGF-I-stimulated effects and that it serves as an important mechanism for regulating cellular responsiveness to IGF-I.</description><subject>Amino Acid Sequence</subject><subject>Animals</subject><subject>Aorta</subject><subject>Arginine</subject><subject>Asparagine</subject><subject>Cell Division - drug effects</subject><subject>Cells, Cultured</subject><subject>Culture Media, Conditioned</subject><subject>Humans</subject><subject>Insulin-Like Growth Factor Binding Protein 1 - antagonists &amp; inhibitors</subject><subject>Insulin-Like Growth Factor Binding Protein 1 - pharmacology</subject><subject>Insulin-Like Growth Factor Binding Protein 5 - biosynthesis</subject><subject>Insulin-Like Growth Factor Binding Protein 5 - chemistry</subject><subject>Insulin-Like Growth Factor Binding Protein 5 - pharmacology</subject><subject>Insulin-Like Growth Factor I - pharmacology</subject><subject>Metalloendopeptidases - metabolism</subject><subject>Muscle, Smooth, Vascular - cytology</subject><subject>Muscle, Smooth, Vascular - drug effects</subject><subject>Muscle, Smooth, Vascular - physiology</subject><subject>Mutagenesis, Site-Directed</subject><subject>Peptide Fragments - chemistry</subject><subject>Peptide Fragments - pharmacology</subject><subject>Point Mutation</subject><subject>Recombinant Proteins - chemistry</subject><subject>Recombinant Proteins - pharmacology</subject><subject>Swine</subject><subject>Thymidine - metabolism</subject><issn>0021-9738</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkbtOwzAYhT2ASikMPACSV4aAHV-SDAyo4lJUCQaYI9txWoNjR7YD4pF4S1K1qmBiOsP_fecfDgBnGF1iXORXj_MFxlWJyAGYIpTjrCpIeQSOY3xDCFPK6ARMKsI5K9gUfD8Hn7SIOgs6mpiES7D1oYO-hcbFwRqXWfOu4Sr4z7SGrVDJh0wa1xi3gv3GNg4yaCIUblTWRpqR-MdfwDGNdxF6B3sflHEaxs77EemGqKyGSlsbxw6oBpuGoE_AYSts1Ke7nIHXu9uX-UO2fLpfzG-WmSK8ShkpBOa8wphphXPeCNWIksu8IkyKXGGuSpojVSDc0qbhsqRN3jDEJSuJ1JySGbje9vaD7HSjtEtB2LoPphPhq_bC1H8vzqzrlf-oGSopx6N_sfVV8DEG3e5VjOrNQvV-oZE9__1rT-7mIT8okZML</recordid><startdate>19971115</startdate><enddate>19971115</enddate><creator>Imai, Y</creator><creator>Busby, Jr, W H</creator><creator>Smith, C E</creator><creator>Clarke, J B</creator><creator>Garmong, A J</creator><creator>Horwitz, G D</creator><creator>Rees, C</creator><creator>Clemmons, D R</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>19971115</creationdate><title>Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture</title><author>Imai, Y ; Busby, Jr, W H ; Smith, C E ; Clarke, J B ; Garmong, A J ; Horwitz, G D ; Rees, C ; Clemmons, D R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-37a1669115ec126dacda86b2935ba2c16c8420c701f4dd6b84d2d506b583be643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Amino Acid Sequence</topic><topic>Animals</topic><topic>Aorta</topic><topic>Arginine</topic><topic>Asparagine</topic><topic>Cell Division - drug effects</topic><topic>Cells, Cultured</topic><topic>Culture Media, Conditioned</topic><topic>Humans</topic><topic>Insulin-Like Growth Factor Binding Protein 1 - antagonists &amp; inhibitors</topic><topic>Insulin-Like Growth Factor Binding Protein 1 - pharmacology</topic><topic>Insulin-Like Growth Factor Binding Protein 5 - biosynthesis</topic><topic>Insulin-Like Growth Factor Binding Protein 5 - chemistry</topic><topic>Insulin-Like Growth Factor Binding Protein 5 - pharmacology</topic><topic>Insulin-Like Growth Factor I - pharmacology</topic><topic>Metalloendopeptidases - metabolism</topic><topic>Muscle, Smooth, Vascular - cytology</topic><topic>Muscle, Smooth, Vascular - drug effects</topic><topic>Muscle, Smooth, Vascular - physiology</topic><topic>Mutagenesis, Site-Directed</topic><topic>Peptide Fragments - chemistry</topic><topic>Peptide Fragments - pharmacology</topic><topic>Point Mutation</topic><topic>Recombinant Proteins - chemistry</topic><topic>Recombinant Proteins - pharmacology</topic><topic>Swine</topic><topic>Thymidine - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Imai, Y</creatorcontrib><creatorcontrib>Busby, Jr, W H</creatorcontrib><creatorcontrib>Smith, C E</creatorcontrib><creatorcontrib>Clarke, J B</creatorcontrib><creatorcontrib>Garmong, A J</creatorcontrib><creatorcontrib>Horwitz, G D</creatorcontrib><creatorcontrib>Rees, C</creatorcontrib><creatorcontrib>Clemmons, D R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Imai, Y</au><au>Busby, Jr, W H</au><au>Smith, C E</au><au>Clarke, J B</au><au>Garmong, A J</au><au>Horwitz, G D</au><au>Rees, C</au><au>Clemmons, D R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture</atitle><jtitle>The Journal of clinical investigation</jtitle><addtitle>J Clin Invest</addtitle><date>1997-11-15</date><risdate>1997</risdate><volume>100</volume><issue>10</issue><spage>2596</spage><epage>2605</epage><pages>2596-2605</pages><issn>0021-9738</issn><abstract>IGFs are pleiotrophic mitogens for porcine smooth muscle cells (pSMC) in culture. The effects of IGFs on cells are modulated by various insulin-like growth factor-binding proteins (IGFBP). IGFBP-5 is synthesized by pSMC and binds to the extracellular matrix. However, IGFBP-5 is also secreted into conditioned medium of cultured cells and is cleaved into fragments by a concomitantly produced protease. These fragments have reduced affinity for the IGFs and cleavage makes it difficult to assess the role of intact IGFBP-5. To study the consequence of accumulation of intact IGFBP-5 in medium, we determined the cleavage site in IGFBP-5 and prepared a protease resistant mutant. Amino acid sequencing of purified IGFBP-5 fragments suggested Arg138-Arg139 as the primary cleavage site. Arg138-Arg139--&gt;Asn138-Asn139 mutations were introduced to create protease-resistant IGFBP-5, which has the same affinity for IGF-I as the native protein. This mutant IGFBP-5 remained intact even after 24 h of incubation and it inhibited several IGF-I actions when added to pSMC culture medium. The mutant IGFBP-5 (500 ng/ml) decreased IGF-I stimulated cellular DNA synthesis by 84%, protein synthesis by 77%, and it inhibited IGF-I stimulated migration of pSMC by 77%. It also inhibited IGF-I stimulation of IRS-1 phosphorylation. In contrast, the same amount of native IGFBP-5 did not inhibit IGF-I actions. The significance of inhibitory effects of the protease resistant IGFBP-5 was further demonstrated in pSMC transfected with mutant or native IGFBP-5 cDNAs. The mutant IGFBP-5 accumulated in culture medium of transfected cells, while native IGFBP-5 was degraded into fragments, PSMC overexpressing the mutant IGFBP-5 also responded poorly to IGF-I compared with mock transfected cells. IGF-I (5 ng/ml) increased [35S]methionine incorporation into control cells by 36% above the basal level, but it did not significantly change (4%) in pSMC cultures that were producing the mutant IGFBP-5. In conclusion, the accumulation of protease-resistant IGFBP-5 in the medium was inhibitory to IGF-I actions on pSMC. This suggests that proteolysis can prevent IGFBP-5 from acting as an inhibitor of IGF-I-stimulated effects and that it serves as an important mechanism for regulating cellular responsiveness to IGF-I.</abstract><cop>United States</cop><pmid>9366575</pmid><doi>10.1172/JCI119803</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-9738
ispartof The Journal of clinical investigation, 1997-11, Vol.100 (10), p.2596-2605
issn 0021-9738
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_508461
source MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
subjects Amino Acid Sequence
Animals
Aorta
Arginine
Asparagine
Cell Division - drug effects
Cells, Cultured
Culture Media, Conditioned
Humans
Insulin-Like Growth Factor Binding Protein 1 - antagonists & inhibitors
Insulin-Like Growth Factor Binding Protein 1 - pharmacology
Insulin-Like Growth Factor Binding Protein 5 - biosynthesis
Insulin-Like Growth Factor Binding Protein 5 - chemistry
Insulin-Like Growth Factor Binding Protein 5 - pharmacology
Insulin-Like Growth Factor I - pharmacology
Metalloendopeptidases - metabolism
Muscle, Smooth, Vascular - cytology
Muscle, Smooth, Vascular - drug effects
Muscle, Smooth, Vascular - physiology
Mutagenesis, Site-Directed
Peptide Fragments - chemistry
Peptide Fragments - pharmacology
Point Mutation
Recombinant Proteins - chemistry
Recombinant Proteins - pharmacology
Swine
Thymidine - metabolism
title Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T20%3A23%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Protease-resistant%20form%20of%20insulin-like%20growth%20factor-binding%20protein%205%20is%20an%20inhibitor%20of%20insulin-like%20growth%20factor-I%20actions%20on%20porcine%20smooth%20muscle%20cells%20in%20culture&rft.jtitle=The%20Journal%20of%20clinical%20investigation&rft.au=Imai,%20Y&rft.date=1997-11-15&rft.volume=100&rft.issue=10&rft.spage=2596&rft.epage=2605&rft.pages=2596-2605&rft.issn=0021-9738&rft_id=info:doi/10.1172/JCI119803&rft_dat=%3Cpubmed_cross%3E9366575%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/9366575&rfr_iscdi=true